Impact of gene patents and licensing practices on access to genetic testing and carrier screening for Tay-Sachs and Canavan disease.
Genetic testing for Tay-Sachs and Canavan disease is particularly important for Ashkenazi Jews, because both conditions are more frequent in that population. This comparative case study was possible because of different patenting and licensing practices. The role of DNA testing differs between Tay-Sachs and Canavan diseases. The first-line screening test for Tay-Sachs remains an enzyme activity test rather than genotyping. Genotyping is used for preimplantation diagnosis and confirmatory testing. In contrast, DNA-based testing is the basis for Canavan screening and diagnosis. The HEXA gene for Tay-Sachs was cloned at the National Institutes of Health, and the gene was patented but has not been licensed. The ASPA gene for Canavan disease was cloned and patented by Miami Children's Hospital. Miami Children's Hospital did not inform family members and patient groups that had contributed to the gene discovery that it was applying for a patent, and pursued restrictive licensing practices when a patent issued in 1997. This led to intense controversy, litigation, and a sealed, nonpublic 2003 settlement that apparently allowed for nonexclusive licensing. A survey of laboratories revealed a possible price premium for ASPA testing, with per-unit costs higher than for other genetic tests in the Secretary's Advisory Committee on Genetics, Health, and Society case studies. The main conclusion from comparing genetic testing for Tay-Sachs and Canavan diseases, however, is that patenting and licensing conducted without communication with patients and advocates cause mistrust and can lead to controversy and litigation, a negative model to contrast with the positive model of patenting and licensing for genetic testing of cystic fibrosis.
Colaianni
Alessandra
A
Center for Public Genomics, Center for Genome Ethics, Law & Policy, Institute for Genome Sciences & Policy, Duke University, Durham, NC 27708, USA.
Chandrasekharan
Subhashini
S
Cook-Deegan
Robert
R
D000581:Amidohydrolases / Q000235:genetics; D017825:Canavan Disease / Q000175:diagnosis* / Q000201:enzymology / Q000235:genetics; D005796:Genes; D006580:Genetic Carrier Screening; D005820:Genetic Testing / Q000191:economics / Q000941:ethics*; D006801:Humans; D007585:Jews / Q000235:genetics; D008007:Licensure, Medical / Q000191:economics / Q000941:ethics*; D010330:Patents as Topic / Q000941:ethics*; D013661:Tay-Sachs Disease / Q000175:diagnosis* / Q000201:enzymology / Q000235:genetics; D054820:beta-Hexosaminidase alpha Chain / Q000235:genetics
C518253:HEXA protein, human; D054820:beta-Hexosaminidase alpha Chain; D000581:Amidohydrolases; C019751:aspartoacylase
Proc Natl Acad Sci U S A. 1984 Sep;81(17):5394-8
6236461
J Inherit Metab Dis. 1995;18(2):215-7
7564250
J Inherit Metab Dis. 1999 May;22(3):263-6
10384383
Am J Med Genet. 1988 Feb;29(2):463-71
3354621
Int J Gynaecol Obstet. 1999 Apr;65(1):91-2
10390111
Wests Fed Suppl. 2003;264:1064-78
15776537
J Law Med Ethics. 2006 Winter;34(4):753-64
17199818
Adv Genet. 2001;44:1-9
11596975
J Mol Diagn. 2003 Feb;5(1):3-8
12552073
Nat Genet. 1993 Oct;5(2):118-23
8252036
Adv Genet. 2001;44:253-65
11596988
J Inherit Metab Dis. 1992;15(3):392-4
1405477
N Y Times Mag. 1998 Dec 6;:56-63, 78, 80,
11647624
Am J Med Genet. 2001 Feb 15;99(1):70-5
11170098
Prog Clin Biol Res. 1977;18:9-10
601099
J Pediatr. 1995 Oct;127(4):511-7
7562269
J Inherit Metab Dis. 1993;16(5):831-6
8295397
Genet Med. 2008 Jan;10(1):57-72
18197058
Obstet Gynecol. 2005 Oct;106(4):893-4
16199656
Obstet Gynecol. 2004 Aug;104(2):425-8
15292027